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ABSTRACT
Introduction: Patients with glaucoma or 
ocular hypertension who do not achieve 
target intraocular pressure (IOP) using one 
hypotensive agent are often transitioned to 
combination therapy. Travoprost 0.004%/
timolol 0.5% fixed combination (TTFC) has 
shown efficacy in patients whose IOP is not 
controlled with other therapies. The goal of 
this study was to assess the efficacy and safety 
of transitioning to TTFC in patients whose IOP 
was uncontrolled on bimatoprost 0.03%/timolol 
0.5%, administered concomitantly or as a fixed 
combination. Methods: This was a prospective, 
open-label, multicenter study of patients with 
open-angle glaucoma or ocular hypertension 
who transitioned to TTFC from fixed or unfixed 
bimatoprost/timolol. Patients self-administered 
TTFC once daily for 8 weeks, and efficacy and 
safety were assessed at baseline, Week 4, and 
Week 8. A symptom survey was administered 
at baseline and Week 8. Both patients and 
investigators reported their medication preference 
at Week 8. Results: A total of 105 patients were 
enrolled in the study. Mean IOP decreased by 
16.5% from baseline after 8 weeks of TTFC 
therapy in the total population, 15.0% in patients 
transitioning from fixed-combination therapy, 
and 20.8% in patients transitioning from unfixed 
therapy (P<0.001 for all groups). The percentage 
of patients reaching target IOP (≤18 mmHg) 
after treatment with TTFC was 69.2% (P<0.001). 
Patients judged stinging/burning to be less severe 
with TTFC than with prior therapy (P=0.029); all 
other symptom frequencies and severities were 
similar for both treatments. Patients preferred 
TTFC over bimatoprost/timolol (fixed and 
unfixed) at a ratio of more than 4:1 (81.4% vs. 
18.6%; P<0.001), and investigators reported a 
nearly five-fold preference for TTFC (83.3% vs. 
16.7%; P<0.001). No unexpected safety concerns 
with TTFC were observed. Conclusion: Travoprost 
0.004%/timolol 0.5% fixed combination 
produced a significant reduction in IOP, with 
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favorable safety and tolerability profiles. Both 
patients and investigators strongly preferred TTFC 
to prior bimatoprost 0.03%/timolol 0.5% therapy.
Keywords: bimatoprost; fixed combination; 
glaucoma; intraocular pressure; prostaglandin 
analog; timolol; travoprost
INTRODUCTION
Patients with glaucoma or ocular hypertension 
who fail to achieve target intraocular pressure 
(IOP) using a single hypotensive agent are 
typically transitioned to combination therapy, 
which can be either the concomitant use of 
two single agents or use of a fixed-combination 
product.1 Fixed-combination products have 
several advantages over concomitant therapy. 
First, they are more convenient because they 
are dispensed from only one bottle. In addition, 
fixed-combination products avoid drug washout 
that can occur when two drugs are administered 
too rapidly in succession, and they reduce 
patients’ lifetime exposure to ocular preservatives. 
The European Glaucoma Society suggests that 
fixed-combination products be used in place of 
two concomitantly administered medications 
whenever possible.1
Fixed-combination travoprost 0.004%/
timolol 0.5% (DuoTrav®; Alcon Laboratories [UK] 
Ltd., Hemel Hempstead, UK) was approved in 
the European Union in 2006 for the treatment of 
patients whose IOP is not controlled with beta-
blocker or prostaglandin analog monotherapy.2 
Comprised of a prostaglandin analog and a beta-
blocker, the travoprost/timolol fixed combination 
(TTFC) demonstrated efficacy and safety 
similar to that of concomitant administration 
of its constituents in a pooled analysis of two 
randomized trials, with the exception of reduced 
ocular hyperemia associated with TTFC (13.7% 
vs. 20.8%, P=0.02).3
The aim of the present study was to assess 
the efficacy and safety of transitioning to 
TTFC from prior therapy with bimatoprost and 
timolol, fixed or unfixed, in patients whose IOP 
was uncontrolled on these agents. Although 
randomized trials have been conducted 
comparing TTFC to other combination products 
under tightly controlled conditions,4-6 the design 
of the present study allowed for examination 
of the effectiveness of TTFC under conditions 
similar to routine clinical practice; specifically, in 
situations in which patients receiving inadequate 
IOP control from one regimen are transitioned to 
another similar product.
METHODS
This prospective, open-label, multicenter 
transition study, conducted in Germany, Spain, 
and the Czech Republic, enrolled patients with 
open-angle glaucoma or ocular hypertension 
whose IOP was uncontrolled (≥19 mmHg) 
using bimatoprost 0.03% (Lumigan®; Allergan, 
Inc., Irvine, CA, USA) and timolol 0.5%, either 
administered concomitantly or as a fixed-
combination product (Ganfort®; Allergan, Inc., 
Irvine, CA, USA). All patients were transitioned to 
TTFC, administered once daily in the evening for 
8 weeks. The protocol was approved by all relevant 
institutional review boards in each country and 
the study was performed in compliance with the 
ethical principles of the Declaration of Helsinki 
and Good Clinical Practice. All participating 
patients provided written informed consent.
Patient Characteristics
Eligible patients were aged ≥18 years with 
a clinical diagnosis of primary open-angle 
glaucoma, pigment dispersion glaucoma, or 
ocular hypertension in both eyes. Patients had 
to have been treated with a stable IOP-lowering 
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regimen of fixed or unfixed bimatoprost 0.03% 
and timolol 0.5% within 4 weeks prior to 
screening and had an IOP in both eyes considered 
safe by the investigator to ensure clinical stability 
of vision and the optic nerve throughout the 
study period. Patients also had to have an IOP 
between 19 and 35 mmHg at any time of day 
in one eye, which would be designated as the 
study eye. In the non-study eye, the IOP had to 
be controlled without pharmacologic therapy 
or on the study medication alone. Patients were 
required to have a best-corrected Snellen visual 
acuity (BCVA) of at least 20/200 in both eyes 
and had to be willing to discontinue the use of 
all ocular hypotensive medications for the entire 
course of the study prior to receiving the study 
medication. In addition, they had to be able to 
follow instructions and be willing and able to 
attend all study visits. Finally, they were required 
to provide informed consent prior to screening.
Patients were excluded if they met any of the 
following criteria: any abnormality preventing 
reliable applanation tonometry in either eye; 
any opacity or patient uncooperativeness that 
restricted adequate examination of the anterior 
chamber of either eye; risk of visual field or 
visual acuity worsening as a consequence of 
participation in the trial, in the investigator’s 
opinion; progressive retinal or optic nerve 
disease from any cause other than glaucoma; 
corneal dystrophies in either eye; concurrent 
infectious/noninfectious conjunctivitis, keratitis, 
or uveitis in either eye; bronchial asthma 
or history of bronchial asthma, bronchial 
hyperreactivity, or severe chronic obstructive 
pulmonary disease that would preclude the 
safe administration of a topical beta-blocker; 
history of ocular herpes simplex; history or risk 
of uveitis or cystoid macular edema; history of 
severe allergic rhinitis; known medical history 
of allergy, hypersensitivity, or poor tolerance 
to any components of the study medication 
that was deemed to be clinically significant 
by the investigator; intraocular conventional 
surgery or laser surgery in either eye <3 months 
prior to screening; use of systemic medications 
known to affect IOP, which have not been on 
a stable course for 7 days prior to screening or 
an anticipated change in the dosage during the 
course of the study; unwillingness to accept the 
risk of darkened iris or eyelash changes; any 
clinically significant, serious, or severe medical 
or psychiatric condition; any condition that, in 
the investigator’s opinion, would interfere with 
optimal participation in the study or present a 
special risk to the patient; and participation in 
any other investigational study within 30 days 
prior to screening. Women who were pregnant 
or lactating or of childbearing potential who were 
not using reliable means of birth control were 
also excluded from the study.
Study Design
All eligible patients completed an ocular 
symptom survey and then received TTFC. They 
were instructed to immediately discontinue 
their previous therapy and to administer one 
drop daily of the study medication at 8:00 pm
for 8 weeks; thus, there was no washout period 
between the patient’s prior ocular hypotensive 
regimen and the study medication. Patients were 
required to return at Week 4 (within 1 hour of 
the time of the IOP assessment at the screening/
baseline visit) for IOP and safety assessments in 
both eyes and at Week 8 (within 1 hour of the 
time of the IOP assessment at the screening/
baseline visit) for IOP and safety assessments and 
completion of the ocular symptom survey and 
global preference response. Investigators also 
completed the global preference response at the 
Week 8 visit for each patient. At both the Week 4 
and Week 8 visits, patients must have been taking 
TTFC as prescribed or the visit was rescheduled.
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Adverse events were noted, monitored, and 
evaluated throughout the study. Patients could 
have been excluded from the trial for any of the 
following reasons: uncontrolled IOP, inability 
to attend scheduled study visits, adverse events, 
personal reasons, inability to follow instructions, 
lost to follow-up, or noncompliance. 
Assessments
Intraocular pressure was assessed using 
Goldmann applanation tonometry. Safety 
assessments were BCVA measurement with 
a Snellen visual acuity chart; slit-lamp 
examination of the eyelids, conjunctiva, cornea, 
iris, anterior chamber, and lens; and adverse 
event assessment. The ocular symptom survey 
comprised questions about the presence, severity, 
duration, and persistence of the following 
common ocular adverse events: dry eye, light 
sensitivity, tearing, burning/stinging, crusting, 
itching, irritation, sandy/gritty feeling, and 
redness. It also contained questions about ease 
of instillation and whether others had noticed 
eye redness. For the global preference question, 
participants and investigators were asked which 
medication they preferred, prior treatment 
(bimatoprost/timolol fixed combination or 
unfixed bimatoprost and timolol) or study 
medication (TTFC).
Study Endpoints
The primary efficacy variable was the mean 
change in IOP from the screening/baseline 
visit to the Week 8 visit for patients receiving 
prior bimatoprost/timolol fixed combination. 
Results were analyzed using a paired t-test. 
Assuming a standard deviation of 3 mmHg and 
a total of 45 evaluable patients receiving prior 
bimatoprost/timolol fixed combination, this 
study was designed to provide an 80% power to 
detect a 1 mmHg difference between both fixed-
combination therapies. 
Statistical Analysis
If both eyes of a patient qualified for the study and 
were treated, then the eye with the higher IOP at 
screening was selected for analysis. If both eyes 
had an equal IOP, then the right eye was selected 
for analysis. The percentage of patients whose 
IOP was reduced to ≤18 mmHg was calculated 
as a secondary outcome measurement using a
Chi-square test. The exploratory objectives were 
to assess the change in the ocular symptom survey 
results from the screening/baseline visit to the 
Week 8 visit and to measure the global preference 
response from both patients and investigators.
A one-way analysis of variance (ANOVA) test was 
performed to evaluate differences in the ocular 
symptom surveys at the screening/baseline visit 
and the Week 8 visit, and global preference 
was analyzed with a Chi-square test. Analyses 
were performed using the intent-to-treat (ITT) 
data set. All data analyses were two-sided and 
an α-level of 0.05 was used to declare statistical 
significance. Statistical analysis was performed 
using SAS (SAS Institute, Cary, NC, USA) by PRN 
Pharmaceutical Research Network, LLC (Dallas, 
TX, USA).
RESULTS
A total of 105 patients from nine sites 
throughout Germany (n=3), Spain (n=3), and the 
Czech Republic (n=3) were enrolled in the study 
and comprised the ITT population. One patient 
was lost to follow-up after the screening/baseline 
visit and was removed from further analysis. 
Another patient discontinued treatment at Week 
4 due to intolerance of study medication, but 
she remained in the ITT population and last 
observation carried forward was employed. 
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Patient demographics are shown in Table 1; 
most patients (83.2%) had a diagnosis of primary 
open-angle glaucoma. Just over 75% of patients 
had received prior fixed-combination therapy 
with bimatoprost/timolol and the remainder 
had received unfixed therapy. The mean age 
of the patient population was 70.3±10.7 years 
(range 37-91 years). Patients had a mean baseline 
IOP of 21.2 mmHg. 
Change in IOP
In the total population, the mean reduction in 
IOP after 8 weeks of treatment with TTFC was 
16.5% (21.2±2.4  vs. 17.7±3.7 mmHg; P<0.001; 
Figure 1). The mean IOP decreased by 15.0% in 
patients who had previously been treated with 
the bimatoprost/timolol fixed combination 
(n=79; 21.4±2.6 vs. 18.2± 3.8 mmHg; P<0.001) 
and by 20.8% in patients who had previously 
received unfixed bimatoprost and timolol (n=26; 
20.7±1.2 vs. 16.4±2.8 mmHg; P<0.001; 20.8%). 
The percentage of total patients reaching target 
IOP (≤18 mmHg) after TTFC therapy was 69.2%, 




 Female 62 (59.0) 
 Male 43 (41.0)
Age (years)
 ≤55 9 (8.6)
 56-65 20 (19.0)
 66-75 42 (40.0)
 ≥76 34 (32.4)
Race
 White 101 (96.2)
 Black 3 (2.9)
 Hispanic 1 (1.0)
Diagnosis
 Primary open-angle glaucoma 88 (83.2)
 Ocular hypertension 16 (15.2)
 Pigment dispersion glaucoma 1 (1.0)
Prior therapy
 Bimatoprost 0.03%/timolol 0.5% 
 fixed combination 79 (75.2)
 Unfixed bimatoprost 0.03% and 
 timolol 0.5% 26 (24.8)



























Week 8 visit (assessing
travoprost/timolol
xed combination)
n=79 n=78 n=26 n=26 n=105 n=104
Figure 1. Mean intraocular pressure (IOP) at screening/baseline visit and after 8 weeks of therapy with travoprost/timolol 
fixed combination (TTFC); intent-to-treat population. *Screening/baseline visit versus Week 8 visit, paired t-test.
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which was a significant improvement compared 
with prior therapy (P<0.001; Figure 2). This 
measurement remained statistically significant 
in both the prior fixed bimatoprost/timolol 
subgroup (65.4%; P=0.007) and the prior unfixed 
bimatoprost and timolol subgroup (80.8%; 
P=0.002).
Ocular Symptom Survey
The percentage of patients who were free of 
specific ocular symptoms was numerically higher 
across seven of the 10 symptom categories 
for TTFC (Week 8 visit assessment) compared 
with prior therapy (screening/baseline visit 
assessment), although none of the differences 
reached statistical significance (Figure 3). 
Stinging/burning were deemed to be less severe 
after treatment with TTFC (P=0.029 for stinging/
burning); the severity of each of the other 
symptoms was judged to be similar between 























Figure 2. Percentage of patients reaching target intraocular 
pressure (IOP; ≤18 mmHg) after 8 weeks of therapy with 
travoprost/timolol fixed combination (TTFC; intent-to-
treat population, n=104). *Bimatoprost/timolol (fixed 
or unfixed) therapy historical control versus travoprost/




























































































Figure 3. Symptom-free frequency associated with prior therapy (at screening/baseline visit) and with travoprost/timolol 
fixed combination (TTFC; at Week 8 visit; intent-to-treat population).
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between prior therapy and study medication 
were noted for the persistence of symptoms 
or the ease of eye drop instillation (P=0.726). 
Examination of patient subgroups showed 
that the symptom profile of the prior fixed-
therapy subgroup was similar to the symptom 
profile of the total patient population, but some 
differences were apparent in the subgroup who 
had previously taken unfixed bimatoprost and 
timolol. Specifically, severity of stinging/burning 
was not statistically different between TTFC and 
unfixed bimatoprost and timolol, but patients 
reported that eye redness was more frequently 
judged by others to be present while they had 
been taking the unfixed bimatoprost and timolol 
(P=0.041).  
Patient and Investigator Preferences
Patients preferred TTFC over prior therapy 
at a ratio of more than 4:1 (81.4% vs. 18.6%; 
P<0.001; Figure 4). When these results were 
analyzed according to patient subgroup, patient 
ratings were more favorable for TTFC compared 
with unfixed bimatoprost and timolol (ratio of 
12:1; 92.3% vs. 7.7%) than compared with fixed 
bimatoprost/timolol (ratio of 3.5:1; 77.6% vs. 
22.4%). Investigators also significantly preferred 
TTFC over prior therapy at a ratio of nearly 
5:1 (83.3% vs. 16.7%; P<0.001). Investigators 
preferentially rated TTFC more favorable 
when compared with unfixed bimatoprost and 
timolol (25.3:1) than with fixed bimatoprost/
timolol (3.7:1).
Safety
A total of 29 adverse events were reported, of 
which 15 were judged to be related to treatment 
with TTFC: ocular hyperemia, ocular burning, 
blurred vision, foreign body sensation, and 
allergic reaction (Table 2). Fourteen of the 15 
treatment-related adverse events were mild in 

























timolol 0.5% xed combination
Figure 4. Global preference response for the intent-to-treat patient population (n=102) and investigators (n=102).
Table 2. Travoprost 0.004%/timolol 0.5%-related adverse 
events in the intent-to-treat population (n=105).
Adverse event Number of events




Foreign body sensation 1
Allergic reaction 1
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(including hyperemia) was classified as severe 
and resulted in treatment discontinuation at 
Week 4. One event, a urinary infection preceded 
by itching, was deemed serious but unrelated 
to study medication. The BCVA did not change 
significantly, and the slit-lamp examination did 
not reveal any significant changes during the 
study, with the exception of a reduction in the 
frequency of abnormal eyelids (P=0.021) after 
8 weeks of TTFC therapy.
DISCUSSION
The current study met its primary objective 
of demonstrating a significant reduction in 
mean IOP in patients who transitioned from 
bimatoprost/timolol fixed combination to 
TTFC. In addition, a significant reduction in 
IOP was also observed in the patient subgroup 
that transitioned from unfixed bimatoprost and 
timolol. Nearly 70% of enrolled patients reached 
target IOP with TTFC therapy. These findings 
indicate that TTFC can further reduce IOP in 
patients already on hypotensive therapy.
Results from the current study are consistent 
with results from previous studies, which 
have demonstrated the efficacy of TTFC in 
patients transitioning from prior therapies.7-9 
These transition studies have all reported 
clinically relevant reductions in IOP in patients 
transitioning from prostaglandin analog plus 
timolol therapy (excluding travoprost plus 
timolol concurrent therapy) to TTFC, ranging 
from 1.4 to 4.4 mmHg reductions.7-9 These real-
world clinical studies provide physicians with 
expectations of how patients may perform when 
transitioning from one regimen to another.
In addition to these transition studies 
examining the performance of TTFC as 
replacement therapy, one randomized, crossover 
study directly compared the efficacy of TTFC to 
the fixed-combination product used as prior 
therapy in the current study, bimatoprost/
timolol fixed combination.4 Results from 
this trial demonstrated that patients’ mean 
IOP was 0.7 mmHg higher with TTFC than 
with bimatoprost/timolol. Although this 0.7 
mmHg difference was statistically significant, 
it may not be clinically relevant. Several studies 
have demonstrated that a decrease of at least
1 mmHg is necessary to produce a clinically 
relevant reduction in the risk of visual field 
progression.10-12 Nonetheless, this disadvantage 
for TTFC is somewhat in contrast to the current 
results, in which patients who had previously 
received bimatoprost/timolol fixed combination 
achieved a significant mean reduction in IOP of 
3.2 mmHg after transitioning to TTFC. 
Differences between the two studies may 
explain these discrepancies. For example, in the 
crossover study, all patients had not reached 
their target IOP with latanoprost/timolol fixed-
combination therapy, whereas the current study 
enrolled patients who had not achieved target 
IOP while on bimatoprost/timolol combination 
therapy. Another potentially important 
difference is the requirement in the crossover 
study for patients to have a baseline IOP of 
<21 mmHg. This resulted in a mean baseline IOP 
of 16.5 mmHg, which is generally considered 
well-controlled in patients with open-angle 
glaucoma, raising the question of why treatment 
was switched to an alternate therapy under 
these conditions. In contrast, eligible patients 
in the current study had to have a baseline 
IOP between 19 and 35 mmHg, which resulted 
in a mean baseline IOP of 21.2 mmHg, clearly 
demonstrating that the group had uncontrolled 
IOP. Because of these differences in the patient 
populations as well as the differences in study 
design, it is difficult to compare these studies.  
Patients in the current study judged TTFC 
and bimatoprost/timolol to have largely 
similar ocular tolerability profiles, albeit with 
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a significant reduction in the severity of ocular 
stinging/burning noted after transitioning to 
TTFC therapy. In addition, no unexpected safety 
concerns with TTFC were observed during the 
course of this clinical trial. Hyperemia, which 
is a class effect of prostaglandin analogs,13 was 
reported as an adverse event in 10% of patients 
while on TTFC. As reported in the symptom 
survey, the incidence of hyperemia was not 
statistically different between prior therapy 
and TTFC therapy. Other ocular side effects 
common to topical ophthalmic medications, 
including burning, blurred vision, and foreign 
body sensation, were infrequently reported and 
were mild in severity; only one case of allergic 
reaction was classified as severe.
In the present study, patients clearly 
demonstrated a preference for TTFC over 
bimatoprost/timolol. Several factors may 
have contributed to this result, including 
the improved ability of TTFC to achieve the 
target IOP, the reduced severity of stinging and 
burning upon instillation of TTFC, or some 
other improved tolerability measure that did 
not reach statistical significance in the ocular 
symptom survey. However, another contributing 
factor was revealed upon examination of the 
preference results by prior therapy subgroups. 
Patients who had been on unfixed bimatoprost 
and timolol had a much greater preference for 
TTFC than did the patients who had already 
been taking fixed-combination therapy (92.3% 
vs. 77.6%). This suggests that patients prefer 
the convenience of a one-bottle regimen. 
Although this undoubtedly impacted the 
preference results, it does not entirely explain 
the imbalance, because even the patients who 
had been receiving bimatoprost/timolol fixed-
combination therapy had a 3.5-fold preference 
for TTFC. 
The design of the present study does present 
some limitations to its interpretation. First, the 
nonrandomized, open-label, transition design 
was not rigorously controlled, increasing the 
odds that the results could have been impacted 
by its design. For instance, transition studies 
tend to have an inherent bias toward the 
medication to which patients are transitioned 
due to the phenomenon known as regression to 
the mean.14 As an example, normal fluctuations 
in the IOP may make it appear as if a patient 
has an elevated IOP with baseline medication 
that necessitates a change in therapy. If by 
the next visit, the IOP appears normalized, it 
is unknown whether this can be attributed to 
the hypotensive efficacy of the new medication 
or if this was simply a regression toward the 
mean IOP. In addition, the short-term focus 
of this study (8 weeks) precludes analysis of 
any adverse events that may appear over a 
longer time period. Finally, although statistics 
were calculated not only for the total patient 
population but also for individual subgroups 
based on prior therapy, the unfixed therapy 
group was underpowered due to its small sample 
size (n=26), making that subgroup’s results 
not as statistically compelling. Nonetheless, 
both the IOP and the safety/tolerability results 
do corroborate those observed in the fixed 
bimatoprost/timolol subgroup. 
In conclusion, the results of the present 
study suggest that physicians with patients who 
have not reached target IOP using bimatoprost 
0.03% and timolol 0.5%, fixed or unfixed, can 
transition them to travoprost 0.004%/timolol 
0.5% fixed combination with the expectation 
of further IOP reduction, a favorable safety 
profile, and a patient preference for the new 
medication. Nonetheless, because of the 
limitations of the design of the present study, 
further research is required to better understand 
the optimal use of TTFC in treating patients 
with primary open-angle glaucoma or ocular 
hypertension.
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